Ascendis Pharma Achieves Week 78 COACH Milestone as YUVIWEL Tops 170 U.S. Enrollments

Pediatric rare disease manufacturing and labeling pipelines are about to get more complex: Ascendis Pharma has completed target enrollment in its pivotal reACHin Trial for infants aged 0 to under 2 years with achondroplasia, signaling planned regulatory filings that will require plant heads and regulatory teams to prepare for an expanded pediatric indication with distinct formulation, dosing, and labeling demands.

On the clinical side, Week 78 data from the Phase 2 COACH Trial showed that combination therapy with once-weekly TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) maintained mean annualized growth velocity at or above the 97th percentile of children of average stature. The treatment-naïve cohort recorded a mean AGV of 7.73 cm/year and a mean ACH height Z-score increase of +1.29 over 78 weeks; the TransCon CNP-experienced cohort posted 7.67 cm/year with a +1.10 Z-score gain. All 21 enrolled children completed Week 78 and remain on therapy, and the safety profile was consistent with previously reported monotherapy data, with low incidence of injection site reactions and generally mild treatment-emergent adverse events.

Separately, the pivotal ApproaCH Trial Week 104 monotherapy data confirmed durable improvements in height, body proportionality, and lower-limb alignment for TransCon CNP alone. Read alongside the reACHin enrollment completion, the dataset positions Ascendis for a multi-indication regulatory strategy that will likely involve 21 CFR Part 211-compliant process validation updates and ICH Q10-aligned lifecycle management documentation as the infant population label is pursued.

Commercial uptake is tracking ahead of typical rare disease launch curves. More than 170 unique YUVIWEL patient enrollments were recorded in the U.S. through June 30, 2026, with over 65% approved for reimbursement. For supply chain and QA leads, that trajectory implies near-term pressure on batch release timelines and serialization compliance as demand scales across a patient population that now spans infants through older children.

The reACHin Trial enrollment completion is the near-term checkpoint to monitor: the timing and content of the regulatory submission package for the infant indication will determine how quickly manufacturing and labeling teams must mobilize for a new pediatric subpopulation.

Source: Ascendis Pharma A/S via GlobeNewswire, August 6, 2026.